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A new viral disease named COVID-19 spread rapidly into a pandemic in early 2020. Most countries have active community
transmission and imposed measures such as social distancing and travel restrictions to mitigate its effect. Many sporting events all
over the globe were canceled or postponed. In this article, we briefly discuss some important topics regarding the COVID-19
pandemic and propose a strategy to manage return to play in professional athletes. We searched the PubMed and Google Scholar
databases to identify articles published through May 12, 2020, using the following keywords: “coronavirus,” “COVID-19,” “SARS-
CoV-2,” “athlete,” and “return to play.” Although athletes have a lower risk of severe disease, preventive measures are still very
important for minimizing time away from training, avoiding potential complications, slowing the pandemic spread, and ultimately
protecting the health of those with a higher risk of complications and death. Athletes may present with mild disease, but com-
plications such as pulmonary fibrosis and myocardial injuries have to be considered. Although still controversial, athletes should be
evaluated before return to play and monitored accordingly afterward via proper clinical assessments and testing.
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In December 2019, a new coronavirus (SARS-CoV-2) was
found to be causing an outbreak of severe acute respiratory
syndrome in Wuhan, China.21 The virus spread rapidly over
several provinces and then globally. The disease caused by
this new virus was named COVID-19 (coronavirus disease
2019). On March 11, 2020, the World Health Organization
declared COVID-19 to be a pandemic because of the large
number of people affected worldwide. Currently, the situa-
tion is in the pandemic phase (phase 6), with increased and
sustained transmission in the general population. Most
countries now have active community transmission and are
trying to mitigate the effect of the disease using measures
such as social distancing and travel restrictions.
In the sports industry, preventive measures among ath-
letes and staff were initially enforced, followed quickly by
events held without spectators and eventually the cancel-
lation or postponement of these events (eg, Summer Olym-
pic Games and Union of European Football Associations
European Football Championship).
Historically, pandemics usually last for 12 to 36 months.
To decrease the duration of this period, a highly effective
treatment protocol, yet to be discovered, and/or achieving
group immunity would be necessary. Vaccine development
usually takes several years, and it is estimated that,
according to the transmissibility of the virus, more than
60% of the population needs to be infected and gain long-
term protection to achieve group immunity.
The clinical manifestations of COVID-19 are mainly
respiratory, and the clinical course is usually mild. How-
ever, a small percentage of patients, especially the elderly
and those with comorbidities, can develop a severe condi-
tion, with several complications and poor outcomes, includ-
ing death. Although the most frequent severe complications
associated with SARS-CoV-2 involve the airways, other
systems, namely the cardiovascular, can be affected.
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The effect of this new disease on athletes’ health and
performance remains unknown, and physicians will face
several challenges before return to play (RTP) is permitted.
In this article, we present a brief discussion of crucial topics
and possible solutions for the management of athletes in
the context of the COVID-19 pandemic.
For this review, we searched the PubMed and Google
Scholar databases to identify English-written articles pub-
lished up to May 12, 2020, using the following keywords:
“coronavirus,” “COVID-19,” “SARS-CoV-2,” “athlete,” and
“return to play.” In addition, we manually searched the
reference lists of most primary articles.
COVID-19 IS CLINICALLY RELEVANT
The clinical presentation of COVID-19 ranges from asymp-
tomatic or mild symptoms to severe illness and death. The
most common symptoms are fever and coughing, with
severe illness occurring in 16% of the patients after hospital
admission.6 In a study of 72,314 cases reported in China,
81% of cases were mild (absent or mild pneumonia); 14%,
severe (hypoxia, dyspnea, >50% lung involvement within
24-48 hours); and 5%, critical (shock, respiratory failure,
multiorgan dysfunction). Of all confirmed cases in this
series, 2.3% resulted in death.20
Pneumonia and acute respiratory distress syndrome are
the main respiratory complications of COVID-19. A meta-
analysis reported respiratory failure or acute respiratory dis-
tress syndrome, a life-threatening lung injury, in 20% of the
patients.22 The long-term effects of these complications
remain to be clarified, but some patients could develop pul-
monary fibrosis. In these cases, reduced lung function may
persist, with a pattern of restrictive lung disease, leading to
decreased exercise capacity.5 Some reports of patients who
recovered from COVID-19 have shown a 20% to 30% drop in
lung function.
Although most complications involve the airways, car-
diac, liver, and kidney dysfunction have also been reported.
In fact, cardiac involvement is somewhat frequent, mainly
in critically ill patients admitted to intensive care units, and
has been implicated in those with the worst outcomes.
Among cardiac complications, myocarditis (including fulmi-
nant cases), malignant arrhythmia, acute heart failure, and
acute coronary syndromes have been reported.8 In some
cohorts, up to 20% of patients have shown elevated troponin
levels, including asymptomatic patients without known car-
diovascular risk factors or previous cardiac disease. This
increased level of troponin corresponds to acute myocardial
injuries and myocarditis, documented in 8.0% of 1527
patients included in a meta-analysis.15 The mechanisms
responsible for acute myocardial injuries in patients with
COVID-19 are poorly understood, but an inflammatory reac-
tion with a cytokine storm is the most likely hypothesis.8
The clinical course of acute disease may be important in
evaluations before athletes resume sports because the per-
sistence of some structural or functional changes, espe-
cially cardiac and respiratory, could influence physical
performance and constitute a trigger for exercise-related
clinical complications, including sudden death.
Not only must clinicians be aware of the potential chronic
complications of COVID-19, but they should also anticipate
the potential long-term adverse effects of some therapeutic
modalities being implemented (eg, anti-inflammatory
drugs, antimalarial drugs, antiviral drugs, steroids, or
immunosuppressants).4
IMMUNE SYSTEM RESPONSE IN ATHLETES
Susceptibility to a viral infection depends largely on the viral
load and virulence, the host’s general health status, and
innate and adaptive immune system responses.16 SARS-
CoV-2 is a highly infectious coronavirus that can be transmit-
ted by asymptomatic carriers over a relatively long period.
While engaging in regular moderate exercise is beneficial in
improving the immune system and preventing viral infec-
tions, an asymptomatic athlete can potentially infect others
in close proximity if preventive measures are not taken.16
The immune system can become temporarily suppressed
when performing acute bouts of prolonged endurance exer-
cise. Competitive athletes must train at increased intensive
workloads to improve their physical condition, potentially
placing them at a higher risk of upper respiratory tract infec-
tions.7,11,16 Athletes should be closely monitored with respect
to training loads, nutritional aspects, and sleeping and mood
patterns to recognize the early signs of overtraining.
HOW TO PREVENT AN INFECTION
Athletes have a higher risk of transmission when they do
not adhere to social distancing or personal hygiene mea-
sures. Athletes frequently train in groups, engage in con-
tact and team sports, share training equipment and
practice surfaces, or travel in aircrafts and other closed-
environment collective vehicles.7,16 SARS-CoV-2 remains
viable in aerosols for up to 3 hours and is detectable on steel
and plastic for up to 3 days.19 Respiratory droplets can float
for a longer time in steam and vapor-rich environments,
such as a changing room, which also enhances the risk of
transmission.16 Some proposed preventive measures are
summarized in Table 1.
TRAINING OUTSIDE . . . WITH A MASK?
Training outside has been permitted in most countries.
If running or cycling outdoors is not feasible, athletes must
comply with social distancing guidelines and other preven-
tive measures. Distancing between individual persons has
been recommended at 1.5 to 2.0 m, which is based on the
dispersal of influenza virus–infected respiratory droplets
(up to 1.829 m or 6 ft)2 and assumes that the majority of
respiratory droplets either fall to the ground or evaporate
before reaching said distance. However, unpublished data
by B. Blocken et al (2020, unpublished) have suggested
that, while this distance may be appropriate for people
standing still, it does not consider the airflow patterns gen-
erated by the person’s movement. This group performed an
aerodynamics study that simulated microdroplet
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dispersion of up to 5 m when slipstream walking at 4 km/h
and up to 10 m when slipstream running at 14.4 km/h, thus
alerting athletes who are training outdoors of the need to
further increase interpersonal distances to be protected.
Wearing a mask is one preventive measure and is recom-
mended when circulating outside of the house, but it can be
burdensome while exercising. It must be kept in mind that
the higher the respiratory flow rate through a surgical
mask, the higher the penetration rate of aerosols; at rest,
the penetration rate is 25%, and it is much higher while
exercising.16 At near maximal ventilation flow rates, a sur-
gical mask provides little protection and may also contribute
to re-aerosolization of the trapped virus. Moreover, above
the second ventilatory threshold and close to maximal load-
ing, masks can hamper exercise performance, an effect
attributed to an increase in inspiratory resistance and inspi-
ratory time, with decreased tidal volume and increased peak
inspiratory pressure and CO2 retention.
16 Therefore, for the
professional athlete performing at the highest intensity,
using a mask may not be recommended.
HOW TO MANAGE AN ATHLETE WITH COVID-19
It is controversial as to whether an athlete can train with
symptoms of an acute infectious illness. Despite not being
evidence-based, the “neck check” rule is often applied in
sports medicine to clear (or not) an athlete to train. If the
symptoms are only “above the neck” (eg, rhinorrhea, nasal
congestion, sore throat, or sneezing), the athlete is allowed
to train at a lower intensity level than usual; if any “below
the neck” symptoms are present (eg, fever, malaise, severe
coughing, gastrointestinal symptoms, or myalgia), the ath-
lete should not train.9
While COVID-19 is associated with high morbidity and
mortality for people older than 60 years or those with chronic
clinical conditions, it is important to remain vigilant with
younger, healthier, and physically fit people.7 Athletes may
experience only mild symptoms such as headaches, sore
throat, rhinorrhea, fatigue, and muscle aches, and, similar
to other young people, might recover over 5 to 7 days.7 There
is, however, evidence that a second phase of possible clinical
deterioration can occur 7 to 9 days after onset.7
As with other illnesses, athletes with COVID-19 who
develop a fever must not be allowed to train and must seek
immediate medical advice, ideally staying at home until told
otherwise.16 Until more is known about this pandemic,
COVID-19 must always be included in the differential diag-
nosis, especially in the presence of unusual symptoms such as
anosmia and ageusia. For that reason, any symptomatic ath-
lete should abstain from training, and return to training after
COVID-19 should be more conservative than with other sim-
pler upper respiratory tract infections, consisting of a more
prolonged rest period (at least 7 days from symptom resolu-
tion).7,16 It is recommended that swabs for reverse transcrip-
tion polymerase chain reaction testing be collected from both
the oropharynx and nasopharynx and that the patient be
quarantined at home for another 2 weeks after hospital dis-
charge. It is reasonable that this 2-week period is also fol-
lowed when clearing the athlete to use any club facilities.3
Toresdahl and Asif18 suggested that, for athletes with
COVID-19, low-intensity training may be attempted during
the period after the complete resolution of symptoms, pro-
vided that the athlete remains isolating at home and that
progression to regular training may occur afterward.15
Although no case reports have been published for athletes
with COVID-19 to date, after the symptomatic period, any
signs or symptoms consistent with postviral fatigue syn-
drome should be identified and managed accordingly.
WHEN AND HOW TO RETURN TO PLAY
Before clearing an athlete to RTP, one must ensure individ-
ual and collective safety conditions. All athletes who have
recovered from COVID-19 should undergo a precompetitive
evaluation. Even those who are asymptomatic or have a mild
disease evolution can present with subclinical lesions asso-
ciated with exercise-induced complications.3 Among these
lesions, cardiac fibrosis and pulmonary fibrosis are the most
relevant, constituting a potential trigger for clinical compli-
cations such as cardiac dysfunction, malignant arrhythmia,
and a reduction of lung capacity. It should be highlighted
that myocarditis is an underdiagnosed cause of sudden
death in athletes that must also be excluded in this setting.
All athletes (whether asymptomatic, mildly sick, or
untested) must be thoroughly evaluated before resuming
exercise training.Thisevaluation maybecomplementedwith
additional examinations, including blood tests, electrocardio-
grams, transthoracic echocardiograms, maximal exercise
testing, 24-hour Holter monitoring, or lung function tests.4
The examinations to include in preparticipation screening
should be selected according to the presentation and severity
of the disease (eg, asymptomatic, mild symptoms, hospital
admission, or intensive care unit admission). Particularly in
exercise testing and lung function assessments, it is impor-
tant to ensure safety and minimize the risk of transmission,
following all recommended protective measures. In the cur-
rent phase of the pandemic, it may be difficult to find avail-
able facilities to perform exercise testing, and thus, other
TABLE 1
Measures to Prevent SARS-CoV-2 Infections in Athletes
Avoid unnecessary contact with infected people or surfaces
Wear a mask whenever outside or in contact with an infected person
Monitor temperature daily before practice
Frequently wash hands
Cover the mouth and nose when coughing or sneezing
Safely discard used tissue paper
Properly cover foods before serving
Use individual cutlery, cups, and dishes
Avoid steam and vapor-rich environments, such as changing rooms
Avoid traveling in closed-environment collective vehicles
Shower before (in contact sports) and after training or competitions
Change and launder clothing used in daily training
Disinfect equipment and training surfaces with diluted bleach
before and after each utilization
Clean any minor abrasions with water and soap before applying
antiseptic solution and bandages
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assessments should be considered for low-risk patients
according to clinical manifestations.4 The infection status
must be verified by viral reverse transcription polymerase
chain reaction and serology-based testing, which is repeated
when indicated. In addition, cardiac signs/symptoms sugges-
tive of myocarditis, ongoing myocardial injuries (troponin
measurements), and arrhythmia (24- to 48-hour Holter mon-
itoring) must be excluded. Athletes with abnormal findings
or those with a more serious clinical evolution of the disease
(eg, need for hospital admission) should undergo more spe-
cific examinations, such as cardiac magnetic resonance
imaging for the suspicion of myocarditis. Athletes with a
Competitive 
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* Individualized decision according to severity of symptoms and clinical evolution
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Figure 1. Clinical evaluation of professional athletes before return to play. All competitive athletes should undergo a clinical
evaluation and be tested for an active SARS-CoV-2 infection. Athletes who have had suspected or confirmed COVID-19 in the
past, or who are now positive, and present with suggestive symptoms or abnormal physical examination findings, or have a history
of recent hospital admission or complications due to COVID-19, should undergo additional assessments according to the
presentation and severity of the disease. Throughout this process, physicians should remain attentive to any athletes developing
new symptoms or those with decreased performance, even if they tested negative previously. CT, computed tomography.
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definite diagnosis of myocarditis must undergo a period of
detraining of 3 to 6 months and should be re-evaluated
before resuming training to confirm the normalization of
left ventricular systolic function, serum biomarkers of a
myocardial injury, and absence of clinically significant
arrhythmia at rest and during exercise.4,18 In Figure 1,
we propose a workflow for evaluating professional athletes
before clearing them to RTP.
A simple mnemonic to reinforce the main steps before
RTP is “TEAM”: Test (virus/immunity status), Evaluate
(clinical signs and symptoms), Assess (blood, heart, and
lungs), and Mask (prevention and protection) (Figure 2).
MENTAL HEALTH
Exercise has a beneficial effect on mental health by reduc-
ing the risk of anxiety and depression. The COVID-19 pan-
demic has caused a paradigm shift in the normal routines
of almost every citizen in the world. Confinement and
social distancing can be detrimental to an athlete’s mental
health. Athletes may currently be facing questions such as
uncertainty of if/when competitions will resume and loss
of income. Other factors, such as excessive unoccupied
time, worse training routines, isolation away from their
home (eg, if under mandatory isolation at a training loca-
tion in a different country), fear of becoming ill or infecting
others, and lack of a healthy sleeping or nutritional rou-
tine, can also be present.7 It is important for support
teams to monitor any athlete under these conditions or
with previous mental health issues to respond more rap-
idly to any imbalances.13
INJURY PREVENTION
Despite the fact that most professional athletes continue
training in isolation during the confinement period, it is
important that sufficient time be provided to achieve the
same fitness level as before the lockdown. Under these con-
ditions, training should ideally be monitored remotely by a
strength and conditioning coach or exercise physiologist for
the correct technical execution of exercises, physiological
parameter monitoring, and injury prevention.12
If sports governing bodies decide to resume and finish
competitions before the beginning of the new season, it will
result in a very congested calendar. A football study showed
that, during a congested period, there is a higher risk of
muscle injuries, specifically the hamstring and quadri-
ceps.1 In addition, 4 days of recovery between matches
has been associated with a higher risk of injuries in com-
parison with that with 6 days of rest.18 According to the
International Olympic Committee consensus statement on
loading in sports, if there are fewer than 4 days of rest
between matches, squad rotation should be considered.17
Team physicians must acknowledge that, upon return-
ing to normal training and competitions this season,
overscheduling competitive moments may play an impor-
tant role in not only acute and overuse musculoskeletal
injuries but also acute illnesses.14,17 More than ever,
load management and injury prevention strategies must
be implemented.10,14,17
“STAY AT HOME” (TAKE-HOME) MESSAGE
COVID-19 is a new disease with an enormous socioeco-
nomic effect. The possibility of a second peak could threaten
the sustainability of national health systems, and political
decisions must take into account the medical and scientific
community. Until there is an effective treatment or cure,
one must be cautious about the reliability of viral and sero-
logical tests.
Sports medicine is facing many challenges during this
new pandemic. While no effective treatment or cure is
available, one must proceed with extreme caution when
resuming sporting activities for both professional and rec-
reational athletes. The mediagenic exposure of elite ath-
letes and the social responsibility of sports will likely
pave the way for the management of return to sports for
the general population, balancing the risks with the multi-
ple benefits of physical exercise for health.
There is still much to be learned, and only by playing as a
“TEAM” can we defeat COVID-19 so that athletes can
return to the playing field as quickly and safely as possible.
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